吃瓜不打烊

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • 吃瓜不打烊 Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Jun 16 2026

Full Issue

FDA Approves Medical-Grade Maggots For Debridement Therapy

The biomedical developer Cuprina Holdings thinks this is the first debridement product to use this particular species, dubbed Medifly Maggots. Maggot debridement therapy has been associated with a lower risk of lower-limb amputation in diabetics with non-healing lesions, MedPage Today reports.

The FDA cleared medical-grade Australian sheep blowfly (Lucilia cuprina) larvae in what maker Cuprina Holdings believes marks the first debridement product to use this particular species. Dubbed Medifly Maggots, the product is indicated for removing dead or infected tissue from non-healing necrotic skin and soft tissue wounds -- such as pressure or neuropathic foot ulcers -- and non-healing traumatic or post-surgical wounds. (Ingram, 6/15)

Despite the promise of freeing people with HIV from taking daily pills, uptake of long-acting injectable antiretroviral therapy (LA-ART) among older Americans remains limited, according to a聽study published聽late last week in JAMA Network Open. Researchers found that just 3% of Medicare beneficiaries with HIV were using the injectable treatment in 2023, two years after the Food and Drug Administration approved the sustained viral suppression regimen. The findings also revealed geographic and racial disparities in who received the therapy, mirroring longstanding disparities in access to HIV care.聽(Bergeson, 6/15)

Replacing two high-dose chemotherapy courses with blinatumomab (Blincyto) significantly improved event-free survival (EFS) in pediatric patients with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (ALL), an interim analysis from a phase III trial showed. (Bassett, 6/15)

Recent Covid vaccination appears to have broad cardioprotective effects, according to a new study, which found reduced risk of events like heart attacks and stroke, hospitalization, and death in people who had received the vaccine. (Chen, 6/15)

Older adults at higher risk for dementia were less likely to have a dementia diagnosis if they received a herpes zoster (shingles) shot, a cohort study using target trial emulation showed. (George, 6/15)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, July 29
  • Tuesday, July 28
  • Monday, July 27
  • Friday, July 24
  • Thursday, July 23
  • Wednesday, July 22
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • 吃瓜不打烊
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 KFF